Tajikistan Medical Device Registration: Quality Management System and GMP Evidence

1. Key takeaways

In Tajikistan, quality management system evidence carries a dual value: it serves both as the quality-dimension evidence of the registration dossier under Article 18(1) and as the credential for exemption from batch-by-batch conformity assessment under Article 13(4). Article 13(4) of Law No. 1893 provides that where the manufacturers and importers of medicines and medical products imported into or produced within the country hold certificates of conformity with good manufacturing practice, the batch-by-batch conformity assessment procedure is waived; Article 1(13) lists good manufacturing practice among the six good pharmaceutical practices. The GRZAN judgment is that this is the most direct route to return on quality system investment in the Tajik market, and the exemption can translate directly into lower clearance costs and faster market access for every shipment.

2. Legal basis

3. Expert insights

Insight 1: Article 1(25) writes international standards for medical products into the definition of contract manufacturing. The definition requires the producing manufacturer to ensure full compliance with the requirements of good manufacturing practice and international standards for medical products. This wording is notable because it mentions good manufacturing practice and international standards together at the statutory level. The GRZAN interpretation is that, for device companies using contract manufacturing, ISO 13485 system evidence and GMP evidence hold parallel status, and both should be included in the quality volume of the registration dossier.

Insight 2: Article 8(5) assigns the approval of good pharmaceutical practices to the Ministry of Health, which determines the recognition standard for system evidence. The provision states that the Ministry of Health approves good pharmaceutical practices in order to provide the population with high-quality, effective and safe medicines and medical products. The implication is that Tajikistan maintains its own texts of good pharmaceutical practices, approved by the Ministry of Health. When preparing GMP evidence, companies should first request the Tajik texts, map the differences against ISO 13485 and the Chinese Good Manufacturing Practice for Medical Devices, and only then decide how to present the evidence.

Insight 3: The inspection powers of Article 9(7) mean system evidence is a matter of continuous compliance, not a one-time document. The provision authorizes the supervisory authority to inspect whether entities engaged in pharmaceutical activities comply with good pharmaceutical practice requirements. Combined with the exemption of Article 13(4), the structure that emerges is: system compliance is exchanged for procedural convenience, and continuous inspection ensures the system does not lapse. GRZAN cautions that if the system fails after the GMP certificate is obtained, both loss of the exemption and inspection risk may be triggered simultaneously, so system maintenance should be built into the annual compliance plan.

Insight 4: The manufacturer accreditation of Article 6(2)(10) is a qualification pathway independent of GMP. The provision lists the accreditation of manufacturers of medicines, medical products and quasi-medicinal products among the ten forms of state regulation. The text does not explain the effect of accreditation, but within the system logic it represents official confirmation of the manufacturing entity’s capability. GRZAN recommends evaluating manufacturer accreditation and the GMP certificate as two separately attainable qualifications, since the two may combine to produce better procedural treatment.

Insight 5: The beneficiaries of the Article 13(4) exemption include importers, which offers an alternative route for small and mid-sized manufacturers. The provision lists manufacturers and importers side by side. For a smaller manufacturer that has not yet obtained a GMP certificate, the exemption may still be triggered if its Tajik importer holds the certificate. GRZAN includes the question of whether a candidate partner holds a GMP conformity certificate as an explicit evaluation criterion when selecting local partners.

4. Practical recommendations

1. Prepare both GMP and ISO 13485 system evidence. Under Article 1(25), contract manufacturing requires compliance with good manufacturing practice and international standards for medical products. Provide both types of evidence in the quality volume and explain their correspondence.
2. Request the Tajik texts of good pharmaceutical practices for a gap comparison. Under Article 8(5), request the currently valid practices from the Ministry of Health, compare them clause by clause against ISO 13485 and the Chinese device GMP, and produce a gap statement as a supplement to the system evidence.
3. Build system maintenance into the annual compliance plan. Under Article 9(7), the supervisory authority inspects compliance with good pharmaceutical practices. Establish an annual internal audit and management review mechanism, and incorporate the Tajik texts into the audit criteria.
4. Use GMP certification status as an evaluation criterion for local partners. Under Article 13(4), a certified importer also triggers the exemption. Include certification status in the evaluation sheet when selecting distributors and importers.
5. Evaluate the manufacturer accreditation regime in parallel. Under Article 6(2)(10), include manufacturer accreditation in planning as an attainable qualification, and compare its benefits horizontally with those of the GMP certificate.

5. Verification checklist

• □ The exemption clause of Article 13(4) and its beneficiaries (manufacturers and importers) have been confirmed
• □ Both GMP and ISO 13485 system evidence have been prepared (Article 1(25))
• □ The Tajik texts of good pharmaceutical practices have been obtained and a gap comparison completed (Article 8(5))
• □ The Tajik texts have been incorporated into the annual internal audit and management review criteria (Article 9(7))
• □ GMP certification status has been included in the evaluation criteria for local partners
• □ The manufacturer accreditation qualification under Article 6(2)(10) has been evaluated
• □ The exemption benefit has been quantified against the annual number of batches

Regulatory information verified as of October 29, 2026.

In the Central Asian market, GRZAN focuses its core capabilities on three areas. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a national track and a Union track coexist; Uzbekistan is an observer state with only the national track; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services: GRZAN acts as the statutory representative of manufacturers in these countries, undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN helps establish a quality management system compliant with ISO 13485 and connects clients with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com